Chargement en cours...
Regulatory considerations in oncologic biosimilar drug development
Biosimilar monoclonal antibodies are being developed globally for patients with different types of solid tumors and hematologic malignancies. Applications for proposed biosimilar monoclonal antibodies are being submitted to the regulatory authorities around the world and may increase patient access...
Enregistré dans:
| Publié dans: | MAbs |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622730/ https://ncbi.nlm.nih.gov/pubmed/25961747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1040973 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|